Aaron Edwards, MSc2, MBA

Co-Founder, CEO ​

With a decade in cellular immunotherapy, Aaron has driven advancements in CAR-T and TCR-T therapies at bluebird bio, Beam Therapeutics (BEAM-201), Eli Lilly, and more. With a Harvard MS/MBA blending science and business, he leads KiraGen Bio’s mission to develop next-generation multiplex-edited cell therapies, overseeing strategy, fundraising, and partnerships.

Tessa Green, PhD

AI Scientist, Head of Immunoinformatics

A biophysicist and data scientist specializing in single-cell transcriptomics and machine learning, Tessa developed scPerturb, a statistical tool for perturbation analysis published in Nature Methods. At Harvard Medical School, she built computational tools for single-cell analysis, generative models, and immunology research. At KiraGen Bio, she leads AI-driven approaches for optimizing gene edits and enhancing CAR-T therapies.

Gabriella Lime, MS

Scientist 

With an MS in Molecular and Cell Biology from Brandeis, Gabriella specializes in gene editing. She has advanced RNA, DNA, and base editing at Beam, Aera, Prime Medicine, and Mammoth Biosciences, optimizing CRISPR and CAR-T systems for ocular, immunology, and oncology applications. At KiraGen Bio, she continues her work in therapeutic gene editing, advancing CAR-T for solid tumors.

Ryan Murray, PhD

Co-Founder, CSO

Ryan drives KiraGen Bio’s research strategy, pioneering next-generation CAR-T therapies for solid tumors. With a decade in cellular engineering at bluebird bio and Beam Therapeutics (BEAM-201), his expertise spans synthetic biology, tumor immunosuppression, and AI-driven gene editing. His PhD from Northeastern focused on overcoming TME-mediated resistance in NSCLC, shaping KiraGen’s approach to tackling solid tumors.

MarkVic Naniong

Associate Director of Platform Development 

MarkVic Naniong brings a decade of biotech experience in CMC development for gene editors, allo CAR-T, and iPSC-derived therapies. At Tome Biosciences, he led iPSC process development, and at Beam Therapeutics, he contributed to BEAM-201’s clinical advancement. Now at KiraGen, he applies his expertise in CMC and platform development to drive R&D and clinical programs.

Avery Houston, BS

Associate Scientist

A biotechnology researcher specializing in T-cell engineering and multiplexed gene editing, Avery has contributed to CAR-T optimization at Chroma Medicine, immune modulation at Dragonfly Therapeutics, and process development at RegenX and Homology Medicines. At KiraGen Bio, he advances CAR-T engineering, target screening, and functional assay development.